endocrinology
CANRISK — Canadian Diabetes Risk Questionnaire
8-item validated questionnaire for screening pre-diabetes and undiagnosed type 2 diabetes in Canadian adults ≥40 years. Score ≥21 = high risk. Similar to FINDRISC/AUSDRISK but adapted for Canadian population including Aboriginal and South Asian groups.
References
- Gao M et al. Validation of the CANRISK questionnaire to screen for prediabetes and undiagnosed type 2 diabetes in Canadian adults. Chronic Dis Inj Can. 2010;30(4):132–140.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Botulinum Toxin Type A (ENT) · Neuromuscular Blocking Agent (Botulinum Toxin)
- Tuberculin purified protein derivative · Mycobacterial antigen for delayed-type hypersensitivity testing
- Ethosuximide · Antiepileptic — T-type Calcium Channel Blocker
- Botulinum toxin type A · Neuromuscular blocker (presynaptic)
- Metformin (Gestational Diabetes / PCOS) · Biguanide — Gestational Diabetes / PCOS
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.